- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07598734
Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty
Doxepin Versus Doxepin and Ramelteon Versus Placebo to Improve Sleep Quality After Primary Total Knee Arthroplasty: A Randomized Controlled Trial
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 4
Kontakte und Standorte
Studienkontakt
- Name: Gerald Y Liao, MS
- Telefonnummer: 617-710-7211
- E-Mail: liaog@uw.edu
Studieren Sie die Kontaktsicherung
- Name: Nicholas M Hernandez, MD
- Telefonnummer: 530-514-1275
- E-Mail: nichern@uw.edu
Studienorte
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98133
- University of Washington Medical Center Hip & Knee Center
-
Kontakt:
- Portia Morgan
- Telefonnummer: 206-668-3674
- E-Mail: morganp9@uw.edu
-
Hauptermittler:
- Nicholas M Hernandez, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Those receiving primary total knee arthroplasty (TKA)
- 80 years or less, age 18 or greater
Exclusion Criteria:
- History of cardiovascular bundle branch block
- Actively taking selecrtive serotoin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or having treatment via counseling/psychotherapy for major depression or anxiety, bipolar, or psychotic disorder
- Pre-operative narcotics (defined as more than 1 prescription in the past 3 months)
- Self-reported use of alcohol in excess of >2 drinks/day (in men) and > 1 drink/day (in women)
- Use of prescription sleep aids (e.g., Ambien, Trazadone) prior to surgery (i.e., melatonin or other OTC sleep aids are permitted)
- History of major sleep disorder (e.g., obstructive sleep apnea (OSA), restless leg syndrome, narcolepsy)
- Pregnant, breastfeeding or planning to become pregnant in the next 3 months post-surgery. No pregnancy testing will be performed; screening will rely solely on participant self-report.
- Unable to take the study medication(s) due to contraindications with other medications the patient uses
- Have been diagnosed with (or are at risk of) narrow-angle or angle-closure glaucoma. In order to be eligible, participants must be able to report that they have had their eyes dilated within the past year without problems.
- Have severe urinary retention or difficulty emptying your bladder.
- Had glaucoma-related eye procedures (e.g., laser iridotomy)
- Ongoing use of glaucoma eye drops.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Doxepin 6 mg
Participants receive doxepin 6 mg and matching placebo orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
|
Experimental: Doxepin 6 mg and Ramelteon 8mg
Participants receive doxepin 6 mg and ramelteon 8 mg orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
Ramelteon 8 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
|
Placebo-Komparator: Placebo
Participants receive 2 matching placebos orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Placebo administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Insomnia Severity Index (ISI) scores (sleep quality)
Zeitfenster: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Insomnia Severity Index (ISI) The Insomnia Severity Index is a 7-item self-reported questionnaire assessing the nature, severity, and impact of insomnia.
Score categories:
|
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS)
Zeitfenster: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.
|
Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS): The KOOS-PS is a 7-item patient-reported outcome measure assessing knee-related physical function, including activities such as rising from bed, putting on socks, rising from sitting, bending to the floor, twisting/pivoting, kneeling, and squatting . Each item is scored on a 5-point Likert scale (None to Extreme). Scores are transformed to a normalized scale ranging from 0 to 100, with higher scores indicating worse physical function (greater disability). |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.
|
|
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR)
Zeitfenster: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR): The KOOS-JR is a patient-reported outcome measure assessing knee pain, stiffness, and functional limitations during activities of daily living over the past week, including tasks such as twisting/pivoting, stair navigation, standing, rising from sitting, and bending . The instrument consists of 7 items scored on a 5-point Likert scale (None to Extreme). Raw scores (range 0-28) are summed and converted to an interval score ranging from 0 to 100, where 0 represents total knee disability and 100 represents perfect knee health (higher scores indicate better outcomes) |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
|
Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10)
Zeitfenster: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10): The PROMIS-10 is a 10-item patient-reported outcome measure assessing global physical health, mental health, pain, fatigue, and social functioning. Items are scored on 5-point Likert scales (e.g., Excellent to Poor; Not at all to Very much), with one pain item scored from 0 to 10. Raw scores are summed and converted to standardized T-scores for Global Physical Health and Global Mental Health, each ranging approximately from 0 to 100 (mean 50, standard deviation 10), where higher scores indicate better health status |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
90-Day Hospital Readmission Status
Zeitfenster: Within 90 days postoperatively
|
Hospital readmission status within 90 days following primary total knee arthroplasty, defined as any unplanned inpatient admission to a hospital occurring within 90 days after the index procedure.
This is a dichotomous outcome (Yes/No), where "Yes" indicates that a readmission occurred and represents a worse outcome.
|
Within 90 days postoperatively
|
|
Medication Compliance
Zeitfenster: 2 weeks postoperatively; 6 weeks postoperatively
|
Medication Compliance: Medication adherence assessed using patient self-report and pill counts when feasible. Self-reported adherence is measured by patient-reported proportion of prescribed doses taken, and pill counts are used to calculate the percentage of medication consumed relative to the prescribed amount. Adherence is expressed as a percentage from 0 to 100%, where higher values indicate better compliance. |
2 weeks postoperatively; 6 weeks postoperatively
|
|
Length of Stay (LOS)
Zeitfenster: Perioperative/Periprocedural
|
Length of Stay (LOS): Length of hospital stay following primary total knee arthroplasty, defined as the number of days from hospital admission to discharge (continuous variable, ≥0 days), where higher values indicate longer hospitalization (worse outcome). |
Perioperative/Periprocedural
|
|
Discharge Destination
Zeitfenster: Perioperative/Periprocedural
|
Discharge Destination: Discharge disposition following primary total knee arthroplasty, categorized as home versus skilled nursing facility. This is a categorical outcome where discharge to a skilled nursing facility represents a worse outcome compared to discharge home. |
Perioperative/Periprocedural
|
|
Postoperative Mobility (Step Count)
Zeitfenster: Perioperative/Periprocedural
|
Postoperative Mobility (Step Count): Postoperative mobility assessed by the number of steps taken during inpatient physical therapy sessions following primary total knee arthroplasty. Step count is recorded as the total number of steps ambulated (continuous variable, ≥0), where higher values indicate better functional recovery. |
Perioperative/Periprocedural
|
|
Level of Assistance Required for Ambulation
Zeitfenster: Perioperative/Periprocedural
|
Level of Assistance Required for Ambulation: Level of assistance required during inpatient physical therapy following primary total knee arthroplasty, categorized as independent, 1-person assist, 2-person assist, or maximal assist. This is an ordinal outcome where greater assistance requirements indicate worse functional recovery. |
Perioperative/Periprocedural
|
|
Postoperative Falls
Zeitfenster: Perioperative/Periprocedural; 3 months postoperatively
|
Postoperative Falls: Occurrence of patient falls during hospitalization or within the follow-up period after primary total knee arthroplasty, defined as any unintentional descent to the ground or lower level documented in the medical record.
This is a dichotomous outcome (Yes/No), where "Yes" indicates a fall occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Delirium
Zeitfenster: Perioperative/Periprocedural; 3 months postoperatively
|
Occurrence of delirium during hospitalization or follow-up after primary total knee arthroplasty, defined by clinical documentation of acute confusional state or use of delirium-related precautions (e.g., 1:1 sitter, physical restraints).
This is a dichotomous outcome (Yes/No), where "Yes" indicates delirium occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
|
Pressure Ulcers (Bed Sores)
Zeitfenster: Perioperative/Periprocedural; 3 months postoperatively
|
Pressure Ulcers (Bed Sores): Development of pressure ulcers during hospitalization or follow-up after primary total knee arthroplasty, defined as localized injury to the skin or underlying tissue documented in the medical record. This is a dichotomous outcome (Yes/No), where "Yes" indicates a pressure ulcer occurred and represents a worse outcome. |
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Opioid Consumption (Morphine Milligram Equivalents)
Zeitfenster: Perioperative/Periprocedural; 3 months postoperatively
|
Postoperative Opioid Consumption (Morphine Milligram Equivalents): Total postoperative opioid use following primary total knee arthroplasty, calculated as cumulative morphine milligram equivalents (MME) administered during hospitalization and follow-up. This is a continuous variable (≥0 mg), where higher values indicate greater opioid consumption (worse outcome). |
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Medical Complications
Zeitfenster: Perioperative/Periprocedural
|
Postoperative Medical Complications: Occurrence of medical complications following primary total knee arthroplasty, including myocardial infarction, venous thromboembolism, cerebrovascular accident, acute kidney injury, respiratory failure, urinary tract infection, pneumonia, gastrointestinal obstruction, and need for intensive care unit (ICU) admission during the same hospitalization. This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome. |
Perioperative/Periprocedural
|
|
Postoperative Surgical Complications
Zeitfenster: Perioperative/Periprocedural; 3 months postoperatively
|
Occurrence of surgical complications following primary total knee arthroplasty, including reoperation, periprosthetic fracture, dislocation, infection, and postoperative stiffness.
This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Nicholas M Hernandez, MD, University of Washington
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- STUDY00024373
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Doxepin 6 mg
-
University of PennsylvaniaPatient-Centered Outcomes Research InstituteNoch keine RekrutierungSchlaflosigkeit | Chronische Schlaflosigkeit | Schlaflosigkeit | Chronische SchlaflosigkeitsstörungVereinigte Staaten
-
Green Cross CorporationSymyooAbgeschlossenChemotherapie-induzierte NeutropenieKorea, Republik von
-
Adynxx, Inc.National Institute on Drug Abuse (NIDA)Zurückgezogen
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin China Pharmaceutical Co., LTD.AbgeschlossenGesunder FreiwilligerChina
-
BioMarin PharmaceuticalBeendetDuchenne-MuskeldystrophieBelgien, Niederlande, Italien, Schweden
-
University of PennsylvaniaTeva Branded Pharmaceutical Products R&D, Inc.Abgeschlossen
-
Haitao Niu, MDAbgeschlossenProstatakrebspatienten, die sich einer radikalen Prostatektomie unterziehen | Prostata CAChina
-
University of AarhusAarhus University HospitalAbgeschlossenFettleibigkeit, BauchDänemark
-
Serpin Pharma, LLCUniversity of VirginiaBeendetLungenentzündung | SARS-CoV-2-InfektionVereinigte Staaten
-
Weill Medical College of Cornell UniversityEisai Inc.Abgeschlossen